Financial Results for the year ended 31st March 2025

Qualified audit opinionEmphasis of matterNet loss reportedResults restatedEBITDA margin compressionRelated-party transactionsResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.9%Reaction day

₹406.95

prior close

₹392.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%+3.0% vs market

Pharmaceuticals peers, median of 147sector+0.1%+2.8% vs sector

On the reaction day the stock moved 3.0 pts more than Nifty Microcap 250 and 2.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-4.8

10m

-4.8

15m

-3.4

30m

-2.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.9-0.1+3.0+0.1+2.8

Next day

+1.2+0.2+1.0-0.0+1.3

+3.9+0.6+3.3+0.8+3.2

+3.2+0.9+2.3+0.3+2.9

+2.7+1.0+1.7+0.0+2.7

+4.4+0.7+3.7-0.7+5.0

+11.8+1.8+10.0-0.1+11.9

15d

+15.8+1.7+14.1-0.9+16.6

+43.8+3.1+40.7-0.8+44.6

+23.3+1.7+21.6+0.4+22.9

+20.0-1.0+21.1-3.0+23.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Kerala Ayurveda Ltd reported a sharp deterioration in its FY25 financial performance, with standalone revenue from operations rising modestly to Rs. 7,268.92 lakhs from Rs. 6,803.65 lakhs (about 7% growth), but the company swung to a net loss of Rs. 1,377.98 lakhs versus a marginal profit of Rs. 5.32 lakhs in FY24. Total expenses surged to Rs. 9,134.18 lakhs, driven by a 75% jump in employee benefit costs (Rs. 2,023.31 to Rs. 3,551.57 lakhs) and an ESOP-related charge of Rs. 622.84 lakhs. The auditor (G. Joseph & Associates) issued a qualified opinion due to an unreconciled bank account balance of Rs. 3.85 lakhs, and an emphasis of matter was added for the restatement of prior period figures under Ind AS 8, which reduced other equity by nearly Rs. 960 lakhs. The board also approved doubling the ESOP pool from 6,66,640 to 12,03,245 shares and seeking shareholder approval for material related-party transactions with Ayurvedagram Heritage Wellness Centre, which exceeded prescribed limits in FY25.

Likely market impact

Shareholders should note a steep swing to losses, a qualified audit opinion, and significant dilution risk from the expanded ESOP pool. An EGM on June 18, 2025 will seek approval for the ESOP expansion and ratification of large related-party transactions with Ayurvedagram Heritage Wellness Centre, both of which could weigh on the stock.